MOORESTOWN, N.J., February 04, 2019 — Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced the upcoming launch of TRHC’s medication decision support software, MedWise™ 2.0, a proprietary software platform for predicting safety, risk and adverse drug events (ADE) associated with polypharmacy, which will be available to users on February 11, 2019.
“The launch of MedWise™ 2.0 represents an important step in bridging the gap between pharmacists and prescribers to advance the safety of patients’ medication regimens, improve outcomes and reduce costs associated with preventable adverse drug events,” said TRHC Chairman and CEO, Calvin H. Knowlton, Ph.D. “With improved interoperability and widespread integration with electronic healthcare records, prescribers will now have real-time access to medication safety recommendations at the point of care to help inform their prescription choices.”
MedWise™ 2.0 will run on an eHealth Medication Risk Mitigation platform that will utilize industry recognized standards for connectivity, compatibility and coordination to improve workflows, patient care and safety. MedWise™ 2.0 will employ the Office of the National Coordinator for Health Information Technology recommended standards for maximum compatibility with care provider systems, SMART on FHIR, the industry standard for connectivity with electronic health records (EHR), and Clinical Decision Support (CDS) Hooks, technology that delivers risk scoring notifications and warnings directly inside the regular workflow of a care provider.
Specifically, MedWise™ will offer Medication Risk Mitigation technology through SMART on FHIR to enable providers’ access to TRHC’s technology directly from their EHR system. The new SMART on FHIR integration will allow pharmacists and care providers to receive deeper clinical insights, provide better continuity of care and ensure greater patient safety.
CDS Hooks specifications available in MedWise™ 2.0 will alert care providers and care coordinators to their individual patients’ Medication Risk Score™ along with the availability of a Medication Safety Review (MSR) for their patients. CDS Hooks will also help ensure that care providers can review recommendations before meeting with a patient, leading to improved adoption of MSR recommendations.
MedWise™ 2.0 is based on TRHC’s proprietary technology for predicting safety risk and ADEs associated with polypharmacy. MedWise™ 2.0 translates the pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with a patient’s medication regimen to formulate meaningful and actionable views of each risks. The technology empowers prescribers to take a more personalized approach to medication management, including medication selection, dosage levels, time-of-day administration and reduction of the total number of medications by eliminating unnecessary prescriptions.
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; acceptance of our products, including MedWise™ 2.0; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 14, 2018, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http://ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.
T: (415) 547-7099